Camizestrant Bests Fulvestrant in HER2̶̶-Negative Advanced Breast Cancer SubsetDecember 8th 2022
Treatment with various camizestrant monotherapy doses lead to survival benefit compared with fulvestrant in a post-menopausal patient population diagnosed with estrogen receptor–positive, HER2-negative advanced breast cancer.
Continuing CDK4/6 Does Not Improve PFS in ER+/HER2- Breast CancerDecember 8th 2022
The combination of palbociclib and fulvestrant beyond progression on prior CDK4/6 inhibitor did not show significant improvements in progression-free survival compared with fulvestrant alone in ER-positive/HER2-negative breast cancer.
Clinical Benefit for ARV-471 Continues to Impress in Expansion Cohort in ER+/HER2– Breast CancerDecember 8th 2022
Results from the VERITAC trial presented at the 2022 San Antonio Breast Cancer Symposium showed that ARV-471 monotherapy may be active in ER-positive/HER2-negative locally advanced/metastatic breast cancer.
Capivasertib Plus Fulvestrant Reduces Risk of Disease Progression or Death in HR+/HER2– Breast CancerDecember 8th 2022
Findings from the phase 3 CAPItello-291 trial show that the combination of capivasertib plus fulvestrant achieved improvement in progression-free survival among patients with hormone-receptor–positive/HER2-negative advanced breast cancer.
Safety of Tucatinib Triplet for HER2+ Breast Cancer Sealed in Real-World AnalysisDecember 8th 2022
Findings from the HER2CLIMB clinical trial of tucatinib combined with trastuzumab and capecitabine verified the safety of the regimen in patients with HER2-positive metastatic breast cancer.
Everolimus Plus Adjuvant ET in Shows No Significant iDFS or OS Advantage in HR+/HER2- Breast CancerDecember 7th 2022
Among premenopausal patients, the addition of everolimus to endocrine therapy improved iDFS and OS, which is hypothesis generating, said Mariana Chavez-MacGregor, MD.
Adjuvant Abemaciclib Improves 4-Year iDFS and DRFS in HR+/HER2– High-Risk Early Breast CancerDecember 7th 2022
The data from 2 years post primary efficacy analysis of monarchE study showed that adjuvant abemaciclib plus endocrine therapy improves invasive disease-free survival.
Study Reveals Racial Disparity Among Patients With Residual Breast Cancer Following Neoadjuvant ChemoDecember 6th 2022
Residual disease after neoadjuvant chemotherapy tumor microenvironment of metastasis doorway density is higher in Black women, potentially explaining poorer outcomes.
Chemotherapy Plus ET May Cause More Cognitive Impairment Than ET Alone in Patients With Breast CancerDecember 6th 2022
Pre- and postmenopausal patient with breast cancer may experience cognitive impairment with chemotherapy and endocrine therapy, according to RxPONDER PRO substudy results presented during SABCS 2022.
Ribociclib Plus ET Yields 46% Reduction in Disease Progression in Pre/Perimenopausal HR+/HR- Advanced Breast CancerDecember 6th 2022
Yielding a 46% reduction in the risk of disease progression of death compared with combination chemotherapy, ribociclib plus endocrine therapy may be a new standard of care for patients with pre/perimenopausal HR-positive, HER2-negative advanced breast cancer
Eganelisib Added to IMPASSION130 Doublet Improves Outcomes in Frontline mTNBCNovember 15th 2022
With the addition of eganelisib to atezolizumab plus nab-paclitaxel, patients with metastatic triple negative breast cancer have longer progression-free survival and better response vs atezolizumab and nab-paclitaxel alone.
Follow-Up Analyzes Safety of DESTINY-Breast03 for HER2+ Breast CancerNovember 15th 2022
Erika P. Hamilton, MD, discusses the purpose of a safety follow-up analysis for the DESTINY-Breast03 trial of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.
Key Efficacy Data from Sub-Group Analyses of Patients from the EMERALD TrialNovember 10th 2022
Taking a closer look at the EMERALD trial, Dr Bardia shares key efficacy outcomes from the sub-group analyses 1) of patients with no prior chemotherapy and 2) comparing elacestrant to fulvestrant or AI.
ELAINE-1 Trial Examines Lasofoxifene in ESR1+, ER+/HER2- Breast CancerNovember 10th 2022
Matthew P. Goetz, MD, discusses the background of the ELAINE-1 study examining lasofoxifene in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer harboring estrogen receptor 1 mutations.
Background for Neoadjuvant Immunotherapy Improving TNBC PrognosisNovember 3rd 2022
Lajos Pusztai, MD, DPhil, discusses the promise of neoadjuvant immunotherapy trials including the KEYNOTE-522 trial evaluating pembrolizumab plus chemotherapy in patients with triple-negative breast cancer.
Trilaciclib Administered Prior to Sacituzumab Reduces Adverse Events in TNBCNovember 2nd 2022
Phase 2 trial of trilaciclib administered prior to sacituzumab govitecan-hziy in patients with unresectable, locally advanced, or metastatic triple-negative breast cancer demonstrates encouraging reductions in adverse events.
Breast Cancer Awareness Month: What to Know for Different Types of Breast CancerOctober 31st 2022
For Breast Cancer Awareness Month Kristina Mirabeau-Beale, mD, MPH, and Bridget Koontz, MD, discuss the different types of breast cancer that clinicians need to be aware of.
Pembrolizumab Shows EFS Benefit in TNBC Without Complete ResponseOctober 27th 2022
Lajos Pusztai, MD, DPhil, discusses key takeaways from analysis of the KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy in the neoadjuvant or adjuvant setting for patients with triple-negative breast cancer.
Fulvestrant Plus Capivasertib Prolongs PFS in HR+ Locally Advanced Metastatic Breast CancerOctober 26th 2022
A progression-free survival advantage and trend toward overall survival benefit has been demonstrated in the CAPItello-291 study of capivasertib and fulvestrant for the treatment of hormone receptor-positive, HER2-low or negative locally advanced or metastatic breast cancer.